Relapsed Multiple Myeloma clinical trials

Explore recruiting relapsed multiple myeloma clinical trials.

Recruiting relapsed multiple myeloma studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Relapsed Multiple Myeloma trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Isatuximab and Autologous Hematopoietic Stem Cell Transplantation for Relapsed Multiple Myeloma Patients (Isabel study)

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

MELFLUFEN FOR ELDERLY MYELOMA PATIENTS IN SECOND OR SUBSEQUENT RELAPSE (MELISSA)

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

A Double-Blind, Randomized, Active Controlled, Parallel-group, Phase 1/3 Study to Compare Pharmacokinetics, Efficacy and Safety of Subcutaneous CT-P44 and Darzalex Faspro in Combination with Lenalidomide and Dexamethasone in Patients with Refractory or Relapsed Multiple Myeloma

Spain, Poland

Therapeutic confirmatory (Phase III) EU CTIS Study details

Teclistamab plus autologous lymphocytes infusion for the treatment of relapsed/refractory Multiple Myeloma (TALIM). MM0125

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

A multi-center phase III randomized study comparing continuous versus fixed duration therapy with Daratumumab, Lenalidomide, and Dexamethasone for relapsed multiple myeloma (CONFIRM)

France

Therapeutic confirmatory (Phase III) EU CTIS Study details

A multicenter phase 2 study of Belantamab mafodotin and Mezigdomide in combination with a phase Ib Safety run in patients with relapsed multiple myeloma following BCMA-targeting CAR-T cells or bispecific antibodies. The IFM 2024-01 clinical trial (BELAMI)

France

Therapeutic exploratory (Phase II) EU CTIS Study details

Relapsed Multiple Myeloma trials by city

Relapsed Multiple Myeloma in Toronto Relapsed Multiple Myeloma in Vancouver Relapsed Multiple Myeloma in Montreal Relapsed Multiple Myeloma in Calgary Relapsed Multiple Myeloma in Edmonton Relapsed Multiple Myeloma in Ottawa Relapsed Multiple Myeloma in Winnipeg Relapsed Multiple Myeloma in Quebec City Relapsed Multiple Myeloma in Hamilton Relapsed Multiple Myeloma in Kitchener Relapsed Multiple Myeloma in London Relapsed Multiple Myeloma in Halifax Relapsed Multiple Myeloma in New York Relapsed Multiple Myeloma in Los Angeles Relapsed Multiple Myeloma in Chicago Relapsed Multiple Myeloma in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease